Biocon commercial rights on biosimilar adalimumab extends to global markets Farhat Nasim8 May 2019 9:45 AM ISTBiocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing...
Lupin to add GLP 1 analog to its diabetes portfolio in India Ruby Khatun Khatun13 Sept 2017 3:07 PM ISTMumbai: Lupin plans to introduce a new class of diabetes drugs in India through in-licensing agreements in order to enhance its diabetes drugs...